scholarly journals Semiparametric methods for evaluating risk prediction markers in case-control studies

Biometrika ◽  
2009 ◽  
Vol 96 (4) ◽  
pp. 991-997 ◽  
Author(s):  
Y. Huang ◽  
M. S. Pepe
Keyword(s):  
Risk Prediction ◽  
Case Control ◽  
Case Control Studies ◽  
Semiparametric Methods

scholarly journals Risk Prediction for Epithelial Ovarian Cancer in 11 United States–Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci

2016 ◽  
Vol 184 (8) ◽  
pp. 555-569 ◽  
Author(s):  
Merlise A. Clyde ◽  
Rachel Palmieri Weber ◽  
Edwin S. Iversen ◽  
Elizabeth M. Poole ◽  
Jennifer A. Doherty ◽  
...  
Keyword(s):  
United States ◽  
Risk Factors ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Risk Prediction ◽  
Case Control ◽  
Genetic Loci ◽  
Case Control Studies ◽  
Epidemiologic Risk

scholarly journals Assessment of biomarkers for risk prediction with nested case–control studies

2013 ◽  
Vol 10 (5) ◽  
pp. 677-679 ◽  
Author(s):  
Qian M Zhou ◽  
Yingye Zheng ◽  
Tianxi Cai
Keyword(s):  
Risk Prediction ◽  
Case Control ◽  
Case Control Studies ◽  
Nested Case Control

scholarly journals A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies

2017 ◽  
Vol 19 (1) ◽  
Author(s):  
Chao Wang ◽  
Adam R. Brentnall ◽  
Jack Cuzick ◽  
Elaine F. Harkness ◽  
D. Gareth Evans ◽  
...  
Keyword(s):  
Texture Analysis ◽  
Risk Prediction ◽  
Case Control ◽  
Case Control Studies

Case-Control Studies

2009 ◽  
Author(s):  
Ruth H. Keogh ◽  
D. R. Cox
Keyword(s):  
Case Control ◽  
Case Control Studies

Clinical Trials in Thrombosis: Secondary Prevention of Myocardial Infarction

1976 ◽  
Vol 35 (01) ◽  
pp. 049-056 ◽  
Author(s):  
Christian R Klimt ◽  
P. H Doub ◽  
Nancy H Doub
Keyword(s):  
Myocardial Infarction ◽  
Secondary Prevention ◽  
Case Control ◽  
Therapeutic Effects ◽  
Case Control Studies ◽  
Definitive Answer ◽  
Inhibition Of Platelet Aggregation ◽  
Prospective Trials

SummaryNumerous in vivo and in vitro experiments, investigating the inhibition of platelet aggregation and the prevention of experimentally-induced thrombosis, suggest that anti-platelet drugs, such as aspirin or the combination of aspirin and dipyridamole or sulfinpyrazone, may be effective anti-thrombotic agents in man. Since 1971, seven randomized prospective trials and two case-control studies have been referenced in the literature or are currently being conducted, which evaluate the effects of aspirin, sulfinpyrazone, or dipyridamole in combination with aspirin in the secondary prevention of myocardial infarction. A critical review of these trials indicates a range of evidence from no difference to a favorable trend that antiplatelet drugs may serve as anti-thrombotic agents in man. To date, a definitive answer concerning the therapeutic effects of these drugs in the secondary prevention of coronary heart disease is not available.

Sign in / Sign up

Export Citation Format

Share Document